HBIO, US4169062043

Harvard Bioscience stock gained 1.92 percent on October 5, 2026

Published on 10/06/2026 at 15:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harvard Bioscience stock posted Q2 2026 revenue of USD 22.7 million, up 11.1 percent from a year earlier. GAAP loss reached USD 2.9 million as adjusted EBITDA rose to USD 1.7 million.

HBIO, US4169062043, Illustration mit AI erstellt.

Harvard Bioscience stock (ISIN US4169062043) gained 1.92 percent to USD 8.50 on Nasdaq on October 5, 2026, with 22,972 shares changing hands. The move leaves the stock 9.57 percent below its 52-week high of USD 9.40, while the company enters the next reporting cycle with second-quarter revenue growth but continuing losses.

Revenue reaches USD 22.7 million

According to StockTitan in the June 30, 2026 Form 10-Q summary, Harvard Bioscience generated USD 22.7 million in second-quarter revenue, an 11.1 percent increase from USD 20.5 million in the same quarter of 2025. Gross profit reached USD 12.6 million, while GAAP gross margin was 55.6 percent, down from 56.4 percent a year earlier.

The earnings mix improved below the gross-profit line but did not yet produce GAAP profitability. StockTitan reported a second-quarter GAAP net loss of USD 2.9 million, compared with a USD 2.3 million loss in the prior-year quarter, while loss per share was USD 0.64.

Adjusted earnings show progress

Harvard Bioscience also reported adjusted EBITDA of USD 1.7 million for Q2 2026, up from USD 1.5 million a year earlier, producing an adjusted EBITDA margin of 7.3 percent. For the six months ended June 30, 2026, revenue totaled USD 43.5 million versus USD 42.2 million in the comparable period, a USD 1.3 million increase.

The balance sheet remains the central counterweight to that operating improvement. At June 30, 2026, cash and cash equivalents stood at USD 6.5 million against USD 36.7 million of debt, while first-half operating cash flow was negative USD 0.3 million, according to StockTitan.

Guidance points to measured growth

The company is targeting 3 percent to 5 percent revenue growth for fiscal 2026, alongside 6 percent to 10 percent adjusted EBITDA growth and a 57 percent to 59 percent gross margin. The guidance range was raised from the earlier 2 percent to 4 percent revenue-growth target, while the gross-margin range was adjusted from 58 percent to 60 percent, according to StockTitan.

Harvard Bioscience develops life-science tools for research, drug discovery, bioproduction and preclinical testing, serving pharmaceutical companies, biotechnology groups, universities and contract research organizations, according to the company's investor overview. Its operating thesis now depends on converting higher sales and adjusted EBITDA into stronger cash generation while managing elevated debt costs.

Harvard Bioscience stock stays below yearly high

Harvard Bioscience stock was last at USD 8.50 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with a session range of USD 8.40 to USD 8.80 and a market capitalization of USD 38.3 million. The 52-week range was USD 3.76 to USD 9.40 on the same date.